$0.10
70.04% yesterday
Nasdaq, Nov 15, 10:16 pm CET
ISIN
US30234E1047
Symbol
EYEN
Sector
Industry

Eyenovia, Inc. Stock price

$0.10
-0.35 77.37% 1M
-0.96 90.39% 6M
-1.98 95.10% YTD
-1.25 92.45% 1Y
-3.55 97.21% 3Y
-2.73 96.40% 5Y
-9.82 98.97% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.24 70.04%
ISIN
US30234E1047
Symbol
EYEN
Sector
Industry

Key metrics

Market capitalization $29.09m
Enterprise Value $34.94m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,164.67
P/S ratio (TTM) P/S ratio 969.67
P/B ratio (TTM) P/B ratio 7.90
Revenue growth (TTM) Revenue growth 2,557.10%
Revenue (TTM) Revenue $30.00k
EBIT (operating result TTM) EBIT $-31.89m
Free Cash Flow (TTM) Free Cash Flow $-30.64m
Cash position $7.19m
EPS (TTM) EPS $-0.73
P/E forward negative
P/S forward 25.43
EV/Sales forward 30.55
Short interest 2.88%
Show more

Is Eyenovia, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Eyenovia, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Eyenovia, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Eyenovia, Inc. forecast:

Buy
100%

Financial data from Eyenovia, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.03 0.03
-
100%
- Direct Costs 1.82 1.82
109% 109%
6,067%
-1.79 -1.79
106% 106%
-5,967%
- Selling and Administrative Expenses 14 14
25% 25%
45,100%
- Research and Development Expense 15 15
42% 42%
51,233%
-31 -31
37% 37%
-102,333%
- Depreciation and Amortization 1.19 1.19
37% 37%
3,967%
EBIT (Operating Income) EBIT -32 -32
37% 37%
-106,297%
Net Profit -38 -38
49% 49%
-126,100%

In millions USD.

Don't miss a Thing! We will send you all news about Eyenovia, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eyenovia, Inc. Stock News

Negative
Reuters
about 13 hours ago
Eyenovia said on Friday it would terminate a late-stage study testing its experimental drug-device combination for pediatric progressive myopia as it failed to meet the main goal.
Neutral
GlobeNewsWire
about 13 hours ago
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint
Neutral
Seeking Alpha
3 days ago
Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO Bren Kern - COO Andy Jones - CFO Conference Call Participants Matthew Caufield - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Lachlan Hanbury-Brown - William Blair Kemp Dolliver - Brookline Capital Markets Len Yaffe - Stoc Doc Partners Operator...
More Eyenovia, Inc. News

Company Profile

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Head office United States
CEO Michael Rowe
Employees 57
Founded 2014
Website www.eyenovia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today